

Thomas B Lam

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7938647/publications.pdf>

Version: 2024-02-01

66
papers

14,787
citations

71102

41
h-index

110387

64
g-index

66
all docs

66
docs citations

66
times ranked

13669
citing authors

#	ARTICLE	IF	CITATIONS
1	EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. <i>European Urology</i> , 2017, 71, 618-629.	1.9	2,497
2	EAU Guidelines on Renal Cell Carcinoma: 2014 Update. <i>European Urology</i> , 2015, 67, 913-924.	1.9	2,445
3	EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer 2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. <i>European Urology</i> , 2021, 79, 243-262.	1.9	1,545
4	EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer. <i>European Urology</i> , 2017, 71, 630-642.	1.9	1,215
5	European Association of Urology Guidelines on Renal Cell Carcinoma: The 2019 Update. <i>European Urology</i> , 2019, 75, 799-810.	1.9	1,022
6	EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. Part II 2020 Update: Treatment of Relapsing and Metastatic Prostate Cancer. <i>European Urology</i> , 2021, 79, 263-282.	1.9	633
7	European Association of Urology Guidelines on Renal Cell Carcinoma: The 2022 Update. <i>European Urology</i> , 2022, 82, 399-410.	1.9	485
8	Systematic Review and Meta-analysis of Diagnostic Accuracy of Percutaneous Renal Tumour Biopsy. <i>European Urology</i> , 2016, 69, 660-673.	1.9	412
9	The Benefits and Harms of Different Extents of Lymph Node Dissection During Radical Prostatectomy for Prostate Cancer: A Systematic Review. <i>European Urology</i> , 2017, 72, 84-109.	1.9	348
10	What Is the Negative Predictive Value of Multiparametric Magnetic Resonance Imaging in Excluding Prostate Cancer at Biopsy? A Systematic Review and Meta-analysis from the European Association of Urology Prostate Cancer Guidelines Panel. <i>European Urology</i> , 2017, 72, 250-266.	1.9	305
11	Medical expulsive therapy in adults with ureteric colic: a multicentre, randomised, placebo-controlled trial. <i>Lancet</i> , 2015, 386, 341-349.	13.7	289
12	Prognostic Value of Biochemical Recurrence Following Treatment with Curative Intent for Prostate Cancer: A Systematic Review. <i>European Urology</i> , 2019, 75, 967-987.	1.9	278
13	Prognostic Performance and Reproducibility of the 1973 and 2004/2016 World Health Organization Grading Classification Systems in Non-muscle-invasive Bladder Cancer: A European Association of Urology Non-muscle Invasive Bladder Cancer Guidelines Panel Systematic Review. <i>European Urology</i> , 2017, 72, 801-813.	1.9	205
14	Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Immune Checkpoint Inhibition Is the New Backbone in First-line Treatment of Metastatic Clear-cell Renal Cell Carcinoma. <i>European Urology</i> , 2019, 76, 151-156.	1.9	190
15	Quality of Life Outcomes after Primary Treatment for Clinically Localised Prostate Cancer: A Systematic Review. <i>European Urology</i> , 2017, 72, 869-885.	1.9	182
16	The Impact of the Extent of Lymphadenectomy on Oncologic Outcomes in Patients Undergoing Radical Cystectomy for Bladder Cancer: A Systematic Review. <i>European Urology</i> , 2014, 66, 1065-1077.	1.9	164
17	Updated European Association of Urology Guidelines: Recommendations for the Treatment of First-line Metastatic Clear Cell Renal Cancer. <i>European Urology</i> , 2018, 73, 311-315.	1.9	138
18	Focal Therapy in Primary Localised Prostate Cancer : The European Association of Urology Position in 2018. <i>European Urology</i> , 2018, 74, 84-91.	1.9	136

#	ARTICLE	IF	CITATIONS
19	Biochemical Recurrence in Prostate Cancer: The European Association of Urology Prostate Cancer Guidelines Panel Recommendations. <i>European Urology Focus</i> , 2020, 6, 231-234.	3.1	131
20	A Systematic Review and Meta-analysis Comparing the Effectiveness and Adverse Effects of Different Systemic Treatments for Non-clear Cell Renal Cell Carcinoma. <i>European Urology</i> , 2017, 71, 426-436.	1.9	123
21	A Systematic Review of Sequencing and Combinations of Systemic Therapy in Metastatic Renal Cancer. <i>European Urology</i> , 2015, 67, 100-110.	1.9	122
22	Oncological Outcomes of Laparoscopic Nephroureterectomy Versus Open Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma: An European Association of Urology Guidelines Systematic Review. <i>European Urology Focus</i> , 2019, 5, 205-223.	3.1	103
23	The 2021 Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Immune Checkpoint Inhibitor-based Combination Therapies for Treatment-naïve Metastatic Clear-cell Renal Cell Carcinoma Are Standard of Care. <i>European Urology</i> , 2021, 80, 393-397.	1.9	103
24	What are the Benefits and Harms of Ureterscopy Compared with Shock-wave Lithotripsy in the Treatment of Upper Ureteral Stones? A Systematic Review. <i>European Urology</i> , 2017, 72, 772-786.	1.9	98
25	Sentinel Node Procedure in Prostate Cancer: A Systematic Review to Assess Diagnostic Accuracy. <i>European Urology</i> , 2017, 71, 596-605.	1.9	98
26	Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Nivolumab plus Cabozantinib Joins Immune Checkpoint Inhibition Combination Therapies for Treatment-naïve Metastatic Clear-Cell Renal Cell Carcinoma. <i>European Urology</i> , 2021, 79, 339-342.	1.9	98
27	Benefits and Harms of Treatment of Asymptomatic Bacteriuria: A Systematic Review and Meta-analysis by the European Association of Urology Urological Infection Guidelines Panel. <i>European Urology</i> , 2017, 72, 865-868.	1.9	89
28	Updated EAU Guidelines for Clear Cell Renal Cancer Patients Who Fail VEGF Targeted Therapy. <i>European Urology</i> , 2016, 69, 4-6.	1.9	85
29	Updated European Association of Urology Guidelines for Cytoablative Nephrectomy in Patients with Synchronous Metastatic Clear-cell Renal Cell Carcinoma. <i>European Urology</i> , 2018, 74, 805-809.	1.9	80
30	Ablative therapy for people with localised prostate cancer: a systematic review and economic evaluation. <i>Health Technology Assessment</i> , 2015, 19, 1-490.	2.8	79
31	Role of Hormonal Treatment in Prostate Cancer Patients with Nonmetastatic Disease Recurrence After Local Curative Treatment: A Systematic Review. <i>European Urology</i> , 2016, 69, 802-820.	1.9	75
32	Potential Benefit of Lymph Node Dissection During Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma: A Systematic Review by the European Association of Urology Guidelines Panel on Non-muscle-invasive Bladder Cancer. <i>European Urology Focus</i> , 2019, 5, 224-241.	3.1	74
33	Risk Stratification Tools and Prognostic Models in Non-muscle-invasive Bladder Cancer: A Critical Assessment from the European Association of Urology Non-muscle-invasive Bladder Cancer Guidelines Panel. <i>European Urology Focus</i> , 2020, 6, 479-489.	3.1	72
34	Updated European Association of Urology Guidelines Regarding Adjuvant Therapy for Renal Cell Carcinoma. <i>European Urology</i> , 2017, 71, 719-722.	1.9	69
35	Long-term Outcomes of Follow-up for Initially Localised Clear Cell Renal Cell Carcinoma: RECUR Database Analysis. <i>European Urology Focus</i> , 2019, 5, 857-866.	3.1	67
36	Systematic Review of the Performance of Noninvasive Tests in Diagnosing Bladder Outlet Obstruction in Men with Lower Urinary Tract Symptoms. <i>European Urology</i> , 2017, 71, 391-402.	1.9	64

#	ARTICLE	IF	CITATIONS
37	Management of Sporadic Renal Angiomyolipomas: A Systematic Review of Available Evidence to Guide Recommendations from the European Association of Urology Renal Cell Carcinoma Guidelines Panel. <i>European Urology Oncology</i> , 2020, 3, 57-72.	5.4	62
38	Risks and Benefits of Adjuvant Radiotherapy After Inguinal Lymphadenectomy in Node-positive Penile Cancer: A Systematic Review by the European Association of Urology Penile Cancer Guidelines Panel. <i>European Urology</i> , 2018, 74, 76-83.	1.9	61
39	Sentinel node biopsy for prostate cancer: report from a consensus panel meeting. <i>BJU International</i> , 2017, 120, 204-211.	2.5	51
40	A core outcome set for localised prostate cancer effectiveness trials. <i>BJU International</i> , 2017, 120, E64-E79.	2.5	48
41	Oncological and functional outcomes of sexual functionâ€‘preserving cystectomy compared with standard radical cystectomy in men: A systematic review. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 539.e17-539.e29.	1.6	43
42	Limitations of Available Studies Prevent Reliable Comparison Between Tumour Ablation and Partial Nephrectomy for Patients with Localised Renal Masses: A Systematic Review from the European Association of Urology Renal Cell Cancer Guideline Panel. <i>European Urology Oncology</i> , 2020, 3, 433-452.	5.4	43
43	Imaging in Suspected Renal-Cell Carcinoma: Systematic Review. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e345-e355.	1.9	39
44	European Association of Urology Guidelines for Clear Cell Renal Cancers That Are Resistant to Vascular Endothelial Growth Factor Receptorâ€‘Targeted Therapy. <i>European Urology</i> , 2016, 70, 705-706.	1.9	34
45	The Impact of Histological Subtype on the Incidence, Timing, and Patterns of Recurrence in Patients with Renal Cell Carcinoma After Surgeryâ€‘Results from RECUR Consortium. <i>European Urology Oncology</i> , 2021, 4, 473-482.	5.4	33
46	Updated Guidelines for Metastatic Hormone-sensitive Prostate Cancer: Abiraterone Acetate Combined with Castration Is Another Standard. <i>European Urology</i> , 2018, 73, 316-321.	1.9	31
47	Intensive Imaging-based Follow-up of Surgically Treated Localised Renal Cell Carcinoma Does Not Improve Post-recurrence Survival: Results from a European Multicentre Database (RECUR). <i>European Urology</i> , 2019, 75, 261-264.	1.9	30
48	2021 Updated European Association of Urology Guidelines on the Use of Adjuvant Pembrolizumab for Renal Cell Carcinoma. <i>European Urology</i> , 2022, 81, 134-137.	1.9	29
49	Use of drug therapy in the management of symptomatic ureteric stones in hospitalised adults: a multicentre, placebo-controlled, randomised controlled trial and cost-effectiveness analysis of a calcium channel blocker (nifedipine) and an alpha-blocker (tamsulosin) (the SUSPEND trial). <i>Health Technology Assessment</i> , 2015, 19, 1-172.	2.8	27
50	Potential of urinary biomarkers in early bladder cancer diagnosis. <i>Expert Review of Anticancer Therapy</i> , 2007, 7, 1105-1115.	2.4	25
51	Patient- and Tumour-related Prognostic Factors for Urinary Incontinence After Radical Prostatectomy for Nonmetastatic Prostate Cancer: A Systematic Review and Meta-analysis. <i>European Urology Focus</i> , 2022, 8, 674-689.	3.1	21
52	Increased use of cross-sectional imaging for follow-up does not improve post-recurrence survival of surgically treated initially localized R.C.C.: results from a European multicenter database (R.E.C.U.R.). <i>Scandinavian Journal of Urology</i> , 2019, 53, 14-20.	1.0	15
53	Diagnostic accuracy of photodynamic diagnosis with 5-aminolevulinic acid, hexaminolevulinic acid and narrow band imaging for non-muscle invasive bladder cancer. <i>Journal of Cancer</i> , 2020, 11, 1082-1093.	2.5	13
54	Reply to Xueliang Zhou and Xinwei Han's Letter to the Editor re: Thomas Van den Broeck, Roderick C.N. van den Bergh, Nicolas Arfi, et al. Prognostic Value of Biochemical Recurrence Following Treatment with Curative Intent for Prostate Cancer: A Systematic Review. <i>Eur Urol</i> 2019;75:967â€‘87. <i>European Urology</i> , 2019, 76, e16.	1.9	10

#	ARTICLE	IF	CITATIONS
55	Evaluation of Oncological Outcomes and Data Quality in Studies Assessing Nerve-sparing Versus Non-nerve-sparing Radical Prostatectomy in Nonmetastatic Prostate Cancer: A Systematic Review. <i>European Urology Focus</i> , 2022, 8, 690-700.	3.1	10
56	Cost Effectiveness of Antimicrobial Catheters for Adults Requiring Short-term Catheterisation in Hospital. <i>European Urology</i> , 2014, 66, 615-618.	1.9	9
57	Pathological nature of renal tumors - does size matter?. <i>Urology Annals</i> , 2017, 9, 330.	0.6	8
58	Re: Neil E. Martin, Laura Massey, Caleb Stowell, et al. Defining a Standard Set of Patient-centered Outcomes for Men with Localized Prostate Cancer. <i>Eur Urol</i> 2015;67:460-467. <i>European Urology</i> , 2015, 68, e123-e124.	1.9	5
59	Reply to E. Jason Abel Letter to the Editor re: Lorenzo Marconi, Saeed Dabestani, Thomas B. Lam, et al. Systematic Review and Meta-analysis of Diagnostic Accuracy of Percutaneous Renal Tumour Biopsy. <i>Eur Urol</i> 2016;69:660-673. <i>European Urology</i> , 2016, 69, e119-e120.	1.9	5
60	Efficacy and safety of different interventions in castration resistant prostate cancer progressing after docetaxel-based chemotherapy: Bayesian network analysis of randomized controlled trials. <i>Journal of Cancer</i> , 2018, 9, 690-701.	2.5	5
61	A Joint Statement from the European Association of Urology Renal Cell Cancer Guidelines Panel and the International Kidney Cancer Coalition: The Rejection of Ipilimumab and Nivolumab for Renal Cancer by the Committee for Medicinal Products for Human Use Does not Change Evidence-based Guideline Recommendations. <i>European Urology</i> , 2018, 74, 849-851.	1.9	3
62	Canadian Urologic Association best practice report: Bone health in prostate cancer. <i>Canadian Urological Association Journal</i> , 2021, 15, 375-382.	0.6	3
63	Measuring the efficacy of antimicrobial catheters. <i>Nursing Times</i> , 2013, 109, 16, 18-9.	0.2	3
64	Shockwave lithotripsy compared with ureteroscopic stone treatment for adults with ureteric stones: the TISU non-inferiority RCT. <i>Health Technology Assessment</i> , 2022, 26, 1-70.	2.8	2
65	Reply to Jae Heon Kim's Letter to the Editor re: Lorenzo Marconi, Saeed Dabestani, Thomas B. Lam, et al. Systematic Review and Meta-analysis of Diagnostic Accuracy of Percutaneous Renal Tumour Biopsy. <i>Eur Urol</i> 2016;69:660-673. <i>European Urology</i> , 2016, 70, e141-e142.	1.9	0
66	Reply to Massimo Valerio, Mark Emberton, and Hashim U. Ahmed's Letter to the Editor re: Henk G. van der Poel, Roderick C.N. van den Bergh, Erik Briers, et al. Focal Therapy in Primary Localised Prostate Cancer: The European Association of Urology Position in 2018. <i>Eur Urol</i> 2018;74:84-91. <i>European Urology</i> , 2019, 75, e23-e24.	1.9	0